Saturday 17 October 2026
Export ZOMDF’s income statement to Excel — free account
Zomedica Corp.
ZOMDF Healthcare Medical Devices
Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.6%, EPS grew 49.3% and free cash flow grew 40.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.08
0.00
0.00%
Follow ZOMDF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.66 | 3.06 | 3.43 | 2.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.82) | (109.00) | (22.37) | (38.41) | |
P/B ratio |
0.66 | 0.85 | 1.06 | 0.91 | |
Price to Tangible BV |
0.99 | 1.28 | 1.61 | 1.40 | |
EV/Sales |
0.88 | 1.41 | 2.06 | 1.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.21) | (2.56) | (4.34) | (4.07) | |
EV/FCF |
(1.07) | (2.43) | (4.08) | (3.62) | |
Quick Ratio |
6.73 | 6.00 | 6.11 | 5.57 | |
Current Ratio |
7.67 | 6.78 | 7.01 | 6.43 | |
Net Debt/EBITDA |
10.96 | 15.88 | 15.26 | 19.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.17 | 0.19 | 0.26 | 0.29 | |
Operating CF/Net income |
0.76 | 0.20 | 1.16 | 0.68 | |
Capex/Depreciation |
(0.08) | (0.10) | (0.29) | (0.46) | |
Research and Development Expense of Revenue |
22.04% | 15.69% | 13.12% | 11.25% | |
Selling, General and Administrative Expense of Revenue |
126.72% | 102.10% | 104.90% | 95.19% | |
Intangible Assets out of Total Assets |
0.31 | 0.31 | 0.31 | 0.32 | |
Share Based Compensation of Revenue |
10.71% | 6.94% | 7.31% | 0.73% | |
Graham Net Nets |
0.68 | 0.53 | 0.42 | 0.48 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(113.75%) | (88.30%) | (19.08%) | (19.20%) | |
Free Cash Flow Yield |
(30.76%) | (18.98%) | (14.73%) | (15.33%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Cash per Share |
0.05 | 0.05 | 0.05 | 0.05 | |
Shareholders Equity per Share |
0.12 | 0.12 | 0.11 | 0.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.12 | 0.12 | 0.11 | 0.11 | |
Free Cash Flow |
(4.80) | (1.09) | (5.77) | (3.37) | |
Working Capital |
56.26 | 54.59 | 51.47 | 48.89 | |
Capital Expenditures |
(0.14) | (0.19) | (0.51) | (0.82) | |
Net Current Asset Value |
53.48 | 52.40 | 49.44 | 47.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.06 | 0.09 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.01 | 3.26 | 3.46 | 4.47 | |
Average Payables |
2.01 | 1.82 | 2.25 | 1.82 | |
Average Inventory |
5.48 | 5.30 | 5.62 | 5.86 | |
Average Assets |
172.51 | 167.20 | 132.26 | 127.31 | |
Average Common Equity |
161.27 | 155.53 | 121.69 | 116.32 |
Columns are period end dates